All In Biotech

Drug Trial Radar · NCT06402513

A Study in Healthy Adult Participants to Assess the Pharmacokinetics, Immunogenicity, Safety, and Tolerability of a Ravagalimab Subcutaneous Formulation in a Pre-Filled Syringe

A Phase 1 Study in Healthy Adult Subjects to Evaluate the Pharmacokinetics, Immunogenicity, Safety, and Tolerability of a Ravagalimab Subcutaneous Formulation in a Pre-Filled Syringe

Last checked: Nov 19, 2026Latest source record: Oct 21, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

12

Actual

Start

Jun 24, 2024

Primary completion

Oct 8, 2024

Study completion Oct 8, 2024

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
May 7, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The objective of this study is to assess the pharmacokinetics, immunogenicity, safety, and tolerability, of subcutaneous formulation of ravagalimab in a pre-filled syringe in healthy adult participants.

Conditions

  • Healthy Volunteers

Interventions

  • RavagalimabDrug

    Subcutaneous Injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Observed Plasma Concentration (Cmax)Time frame: Approximately up to 71 days
  2. Time to Maximum Observed Plasma Concentration (Tmax)Time frame: Approximately up to 71 days
  3. Apparent Terminal Phase Elimination Rate Constant (β)Time frame: Approximately up to 71 days
  4. The Terminal Phase Elimination Half-Life (t1/2)Time frame: Approximately up to 71 days
  5. The Area Under the Plasma Concentration-Time Curve (AUC) from Time 0 to Time of the Last Measurable Concentration (AUCt)Time frame: Approximately up to 71 days
  6. The Area Under the Plasma Concentration-Time Curve (AUC) from Time 0 to Infinity (AUC∞)Time frame: Approximately up to 71 days
  7. Number of Anti-drug antibody (ADA) TitersTime frame: Approximately up to 71 days
  8. Number of Participants with Adverse EventsTime frame: Approximately up to 85 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Acpru /Id# 265325

    Grayslake, Illinois

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.